Ruxolitinib (INCB018424)

Ruxolitinib (INCB018424)

Cat. No.: DIA-0230311

Size: 50 mg Size: 500 mg Size: Customer Size
Product Information
CAS No. 941678-49-5
Formula C17H18N6
Molecular Weight 306.37
SMILES N#CCC(C1CCCC1)[N]2C=C(C=N2)C3=NC=NC4=C3C=C[NH]4
Target JAK1/2
Product Description Ruxolitinib (INCB018424) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, >130-fold selectivity for JAK1/2 versus JAK3.
Format & Storage
Purity > 99%
Shipping Shipped on dry ice.
Storage Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month
Solubility Overview Soluble in DMSO
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
logo

Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.

Quick Links
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.
Top